The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies that neutralize the intended SARS-CoV-2 variant target among recipients, according to a press release from ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

In a new study published in Nature Immunology, researchers at Boston Children's Hospital demonstrated that pairing the original COVID-19 mRNA vaccine with an immune system enhancer, known as an ...

The immune response to COVID-19 vaccination unfolds through a finely orchestrated sequence of innate and adaptive events. Initial recognition of vaccine-derived antigens by pattern recognition ...

Findings from this trial reinforce the preclinical data supporting the approval of the LP.8.1-adapted COVID-19 vaccine for the 2025-2026 season. Topline results were announced from a phase 3 trial ...

Researchers at University of California San Diego School of Medicine have found that a natural fungal supplement taken at the time of COVID-19 vaccination reduced short-term vaccine side effects and ...

The concept of vaccination was first developed in the 19th century when Dr. Edward Jenner made the observation that milkmaids were immune to a deadly virus known as smallpox. He realized that most ...

As a number of federal policies impact availability of COVID-19 vaccines, Rhode Island is looking to preserve access through protective measures. The moves followed a recent U.S. Food and Drug ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...